Tonix Pharmaceuticals Holding (TNXP) Cash & Equivalents (2010 - 2026)

Tonix Pharmaceuticals Holding's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $155.1 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 17.75% year-over-year to $155.1 million in Q1 2026; TTM through Mar 2026 was $155.1 million, a 17.75% increase from a year earlier, with the FY2025 full-year figure at $207.6 million, up 108.3% from the prior year.
• Cash & Equivalents retreated to $155.1 million in Q1 2026 per TNXP's latest filing, from $207.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $207.6 million in Q4 2025 and bottomed at $24000.0 in Q2 2024.
• The 5-year median for Cash & Equivalents is $99.7 million (2024), against an average of $88.5 million.
• Across the five-year window, Cash & Equivalents sank 99.91% in 2024 and surged 422816.67% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $120.5 million in 2022, then plunged by 78.54% to $25.8 million in 2023, then soared by 285.62% to $99.7 million in 2024, then soared by 108.3% to $207.6 million in 2025, then decreased by 25.3% to $155.1 million in 2026.
• Per Business Quant, the three latest TNXP Cash & Equivalents figures stand at $155.1 million (Q1 2026), $207.6 million (Q4 2025), and $97.6 million (Q3 2025).